Immunosuppression in clinical practice: AAApproaches to individualized therapy

Andrew Chan, Olaf Stüve, Nicolas Von Ahsen

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies.

Original languageEnglish (US)
Pages (from-to)22-27
Number of pages6
JournalJournal of neurology
Issue numberSUPPL. 6
StatePublished - Dec 2008


  • Azathioprine
  • Cyclophosphamide
  • Methotrexate
  • Mitoxantrone
  • Pharmacogenetics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Immunosuppression in clinical practice: AAApproaches to individualized therapy'. Together they form a unique fingerprint.

Cite this